Fortress Biotech, Inc. (FBIO)
| Market Cap | 62.70M -19.6% |
| Revenue (ttm) | 69.99M +12.3% |
| Net Income | 91.84M +2,411.2% |
| EPS | 2.68 |
| Shares Out | 33.35M |
| PE Ratio | 0.70 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,598 |
| Open | 1.920 |
| Previous Close | 1.990 |
| Day's Range | 1.755 - 1.935 |
| 52-Week Range | 1.755 - 4.530 |
| Beta | 1.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About FBIO
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycl... [Read more]
Financial Performance
In 2025, Fortress Biotech's revenue was $63.26 million, an increase of 9.69% compared to the previous year's $57.68 million. Losses were -$1.88 million, -96.63% less than in 2024.
Financial StatementsNews
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025
Fortress Biotech Earnings Call Transcript: Q3 2026
Q3 revenue grew 8% YoY, with EMROSI sales, prescriptions and prescriber numbers advancing; EBITDA was positive for a second quarter. A national formulary win covering over 25 million lives is expected to support access and ASP improvement in 2027, subject to patient mix and deductible-reset timing.
Fortress Biotech Earnings release: Q3 2026
Fortress Biotech released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Fortress Biotech Quarterly report: Q3 2026
Fortress Biotech has published its Q3 2026 quarterly earnings report on November 12, 2026.
Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues were $19.0 million for the third quarter of 2026 Emrosi ® revenues of $9.0 million increased 84% compared to the third quarter of 2025 Company to hold conference call today at 4:30 p.m....
Fortress Biotech unit licenses FB-607 from Cedars-Sinai
Fortress Biotech (FBIO) announced that a majority-owned and controlled subsidiary of Fortress has entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607, a novel approach to...
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
MIAMI, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhan...
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid...
Journey Medical Corporation to Participate in September 2026 Investor Conferences
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marke...
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 mi...
Fortress Biotech Earnings Call Transcript: Q2 2026
Q2 2026 saw 23% revenue growth year-over-year, driven by Emrosi's strong prescription and prescriber gains, improved payer coverage, and higher ASP. EBITDA turned positive, and the launch of Eurax Cream is expected to further boost growth. Cash position improved to $25.6 million.
Fortress Biotech Quarterly report: Q2 2026
Fortress Biotech has published its Q2 2026 quarterly earnings report on August 12, 2026.
Fortress Biotech Earnings release: Q2 2026
Fortress Biotech released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on ...
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on dev...
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeuti...
Fortress Biotech Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with two motions: electing directors for the next term and ratifying KPMG as auditors for 2026. Both motions were approved by shareholders, concluding the formal business.
Fortress Biotech Slides: Corporate presentation
Fortress Biotech has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Fortress Biotech Transcript: A.G.P.'s Annual Virtual Healthcare Conference
The company leverages a scalable, diversified model to acquire and develop clinical-stage medicines, generating value through royalties, equity, and milestones. Recent monetizations and FDA approvals have strengthened cash flow, while AI-driven asset identification and a robust pipeline position the company for continued growth.
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on d...
Fortress Biotech price target raised to $5 from $4.50 at Alliance Global
Alliance Global raised the firm’s price target on Fortress Biotech (FBIO) to $5 from $4.50 and keeps a Buy rating on the shares, citing increased value from its cash balance…
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 mill...